

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Nafizal Hossain et al.	Art Unit	:	Unknown
Serial No.	:	10/581,171	Examiner	:	Unknown
Filed	:	May 31, 2006	Conf. No.	:	1661
Title	:	NOVEL COMPOUNDS			

MAIL STOP AMENDMENT
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request. Copies of International Search Reports for WO 2004/005295, WO 2005/037814, WO 2005/040167, WO 2005/049620 and WO 2005/061499 are also enclosed.

Applicants provide a listing below of commonly owned co-pending U.S. patent applications that are included on the PTO-1449. Please note that the commonly owned co-pending U.S. patent applications were filed as U.S. national phase patent applications under 35 U.S.C. §371, and therefore the listing includes a reference to the PCT publication number for each of commonly owned co-pending U.S. patent applications.

The PTO-1449 lists the commonly owned co-pending U.S. patent applications by their corresponding published PCT publication numbers. The published U.S. patent applications are listed on the PTO-1449 under both the U.S. publication numbers and the PCT publication numbers.

U.S. Patent Application Serial No./ Published U.S. Patent Application	Corresponding Published PCT Patent Application
US-2005-0245741-A1	WO 2004/005295 (previously cited in 5/31/06 IDS)
US 2007-0021498-A1	WO 2005/037814
10/575,525	WO 2005/040167
10/579,545	WO 2005/049620
10/583,468	WO 2005/061499

Applicant : Nafizal Hossain et al.
Serial No. : 10/581,171
Filed : May 31, 2006
Page : 2 of 2

Attorney's Docket No.: 06275-513US1 / 101293-1P US

This statement is being filed before the receipt of a first Office Action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 06275-513US1.

Respectfully submitted,

Date: March 8, 2007

Catherine M. McCarty Reg. No. 54,301
for Janis K. Fraser, Ph.D., J.D.
Reg. No. 34,819

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

21579908.doc

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-513US1	Application No. 10/581,171
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Nafizal Hossain et al.		
		Filing Date May 31, 2006	Group Art Unit Unknown	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	4,010,201	03/01/1977	Lednicer			
	AB	4,263,317	04/21/1981	Martin et al.			
	AC	US-2005-0245741-A1	11/03/2005	Hossain et al.			
	AD	US 2007-0021498 A1	01/25/2007	Hossain			

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation
							Yes No
	AE	EP 0004952	10/31/1979	Europe			Abstract
	AF	EP 0417631	03/20/1991	Europe			Abstract
	AG	EP 0722941	07/24/1996	Europe			
	AH	EP 1061076	12/20/2000	Europe			
	AI	WO 92/10096	06/25/1992	WIPO			
	AJ	WO 96/36625	11/21/1996	WIPO			
	AK	WO 01/30780	05/03/2001	WIPO			
	AL	WO 03/037271	05/08/2003	WIPO			
	AM	WO 2005/037814	04/28/2005	WIPO			
	AN	WO 2005/040167	05/06/2005	WIPO			
	AO	WO 2005/049620	06/02/2005	WIPO			
	AP	WO 2005/061499	07/07/2005	WIPO			

Other Documents (Include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AQ	Mehrotra et al., "Spirocyclic Nonpeptide Glycoprotein IIb-IIIa Antagonists. Part 3: Synthesis and SAR of Potent and Specific 2,8-Diazaspiro[4.5]decanes", <i>Bioorganic & Medicinal Chemistry Letters</i> 12:1103-1107 (2002)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	